Recovery of perfluorinated polyether oils from grease matrices incorporating extraction aids by carbon dioxide extraction
US-2016319216-A1 · Nov 3, 2016 · US
Method for pretreatment and method for analysis of lenalidomide in biological sample
US10725057B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10725057-B2 |
| Application number | US-201515312777-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 21, 2015 |
| Priority date | May 22, 2014 |
| Publication date | Jul 28, 2020 |
| Grant date | Jul 28, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the deproteinization under acidic conditions of the biological sample containing lenalidomide enantiomer, and the lenalidomide enantiomer can be simply and accurately quantitatively analyzed by subjecting to HPLC the biological sample that has been pretreated in such a way.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for quantifying enantiomers of lenalidomide in a biological sample, comprising pretreating a biological sample containing enantiomers of lenalidomide by deproteinizing the biological sample under acidic conditions to minimize racemization of the enantiomers of lenalidomide relative to a method where a biological sample containing enantiomers of lenalidomide is not deproteinized under acidic conditions; and separating and quantifying the enantiomers of lenalidomide by high-performance liquid chromatography of the biological sample containing enantiomers of lenalidomide that has been pretreated. 2. The method according to claim 1 , wherein the acidic conditions are pH 5 or lower. 3. The method according to claim 1 , wherein an acid selected from among perchloric acid, trichloroacetic acid, trifluoroacetic acid, metaphosphoric acid, hydrochloric acid, succinic acid and maleic acid is added. 4. The method according to claim 1 , wherein the biological sample is blood, serum, blood plasma, urine, saliva, breast milk, spinal fluid, semen, tissue or microsomes. 5. The method according to claim 1 , wherein the enantiomer of lenalidomide is the S-form. 6. The method according to claim 1 , wherein the enantiomer of lenalidomide is the R-form.
Assignees
Inventors
Classifications
- B01D15/12Primary
relating to the preparation of the feed · CPC title
Biological material, e.g. blood, urine (G01N33/02, G01N33/26, G01N33/44, G01N33/46 take precedence); Haemocytometers (counting blood corpuscules distributed over a surface by scanning the surface G06M11/02) · CPC title
- G01N33/94Primary
involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors} · CPC title
Pressure or speed conditioning · CPC title
Chiral chromatography · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10725057B2 cover?
- The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the…
- Who is the assignee on this patent?
- Shiseido Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification B01D15/12. Mapped technology areas include Operations & Transport.
- When was this patent published?
- Publication date Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).